. 24/7 Space News .
TECH SPACE
RedHill Biopharma announces positive new data with Opaganib for nuclear radiation injury
by Staff Writers
Tel Aviv, Israel (SPX) Nov 18, 2022

illustration only

RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, has announced positive in vivo results from a new pre-clinical study evaluating the effects of opaganib[1] on radiation-induced hematologic and renal toxicity, undertaken by RedHill and its partner Apogee Biotechnology Corporation ("Apogee"). The results, suggesting that opaganib exerts a protective impact on key hematological and kidney function parameters following total body irradiation (TBI), are consistent with recently published U.S. government-funded in vivo opaganib data[2] and are further supportive of opaganib's planned development under the Animal Rule for nuclear radiation protection.

Lynn W. Maines, PhD., Apogee's VP of Research, said: "These results, as well as the established scientific understanding that disruption of S1P production reduces damaging pathologic inflammation, further support the hypothesis that opaganib's inhibition of SK2, and subsequent reduction S1P production, suppresses Heme-ARS and kidney damage by lethal total body irradiation, and may play a key role in protecting against generalized radiation injury."

"These new results add to, and are consistent with, the positive indications towards opaganib's radioprotective capabilities reported in the recent peer-reviewed International Journal of Molecular Sciences (IJMS) publication and support further studies of opaganib in this indication," said Dr Mark Levitt, MD, PhD, Chief Scientific Officer at RedHill. "Our assessment of the pathway towards approval, and following recent discussions with key government agencies, gives us an understanding of the progress already made, and of the areas of ongoing work still to be completed, which we believe can be done in an expedited manner given the prevailing need for new radioprotective treatment options."

Recently published, U.S. government funded results, from eight preclinical studies and additional experiments, indicate opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy. These results indicate that opaganib may protect normal tissue from damage due to ionizing radiation exposure or cancer radiotherapy, improve antitumor activity and response to chemoradiation, and enhance tolerability and survival.

Opaganib is a novel oral small molecule sphingosine kinase 2 (SK2) inhibitor that is potentially suitable to current government research priorities for material threat medical countermeasures suitable for central stockpiling for use in mass casualty nuclear radiation incidents. Opaganib can be administered 24 hours or later after radiation exposure, is highly stable with a more than five-year shelf-life, easy to administer and distribute, and demonstrated its clinical safety profile in various human clinical studies and expanded access uses in other indications.

Multiple discussions with government agencies in the U.S. and internationally are ongoing regarding funding and medical countermeasure development pathways.

Sponsors of approved medical countermeasures product applications may be eligible for a medical countermeasure Priority Review Voucher.


Related Links
RedHill Biopharma
Space Technology News - Applications and Research


Thanks for being there;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Monthly Supporter
$5+ Billed Monthly


paypal only
SpaceDaily Contributor
$5 Billed Once


credit card or paypal


TECH SPACE
How does radiation travel through dense plasma
Rochester UK (SPX) Nov 18, 2022
Most people are familiar with solids, liquids, and gases as three states of matter. However, a fourth state of matter, called plasmas, is the most abundant form of matter in the universe, found throughout our solar system in the sun and other planetary bodies. Because dense plasma-a hot soup of atoms with free-moving electrons and ions-typically only forms under extreme pressure and temperatures, scientists are still working to comprehend the fundamentals of this state of matter. Understanding how atoms ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

TECH SPACE
AFRL awards contract for pioneering spacecraft in region of Moon

Calnetix Technologies' high-speed blower system delivered to ISS

SmartSat CRC and NASA team up to collaborate on astronaut emergency communications

S.S. Sally Ride delivers experiments to International Space Station

TECH SPACE
NASA Awards SpaceX Second Contract Option for Artemis Moon Landing

Rocket Factory Augsburg to use test infrastructure at DLR Lampoldshausen

SpaceRyde announces multiple launch agreements with ISILAUNCH

To orbit and back with Space Rider

TECH SPACE
Space exploration goes underground

Try, Try Again: Sols 3655-3656

A rover for Mars' moon Phobos

Gediz Vallis Ridge Rising: Sols 3650-3652

TECH SPACE
Shenzhou XIV taikonauts perform third spacewalk

China launches spacecraft carrying cargo for space station

China's cargo spacecraft sets new world record

Next-generation rocket for astronauts expected in 2027

TECH SPACE
AE Industrial Partners completes investment in York Space Systems

Rocket Lab to supply satellite separation systems for Tranche 1 Transport Layer vendors

Maxar-built Galaxy 31 and Galaxy 32 for Intelsat performing properly after launch

Rocket Lab to launch HawkEye 360's Cluster 6 satellites in December

TECH SPACE
How does radiation travel through dense plasma

Turning asphaltene into graphene for composites

ESA experiences COP27 using a space-empowered metaverse

Revolutionizing radar signal processing

TECH SPACE
Early planetary migration can explain missing planets

Oldest planetary debris in our galaxy found from new study

Do you speak extra-terrestrial?

Starshade competition challenges students to block starlight for observing exoplanets

TECH SPACE
Mars and Jupiter moons meet

NASA studies origins of dwarf planet Haumea

NASA study suggests shallow lakes in Europa's icy crust could erupt

Sharpest Earth-based images of Europa and Ganymede reveal their icy landscape









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.